Segment Reporting (Tables)

6 Months Ended

Jun. 30, 2025

Schedule Of Segment Reporting Information By Segment

The following table presents reportable segment net loss, including significant expenses regularly provided to the CODM, attributable to the Company’s reportable segment for the three and six months ended June 30, 2025 and 2024 (in thousands):


	Three Months Ended June 30,						Six Months Ended June 30,
	2025			2024			2025			2024
Direct research and development expense by program:
Bempikibart	$	1,807		$	8,059		$	4,571		$	13,320
ADX-097		914			1,517			1,483			2,601
Discovery and other		46			266			89			491
Personnel-related costs (excluding stock-based compensation)		2,836			3,796			7,385			9,528
Other G&A expenses		2,156			2,716			4,938			4,591
Interest income, net		(284	)		(1,068	)		(655	)		(1,248	)
Other segment items (1)		2,014			1,692			2,709			(13,334	)
Total segment net loss	$	9,489		$	16,978		$	20,520		$	15,949

(1) Other segment items are included in order to reconcile to total segment net loss. Other segment items include non-cash items such as depreciation and amortization expense and stock-based compensation expense, gains and losses on the change in fair value of convertible notes, change in fair value of contingent value rights and loss from equity method investment.

Q32 Bio Inc. 10-Q